Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $95.0 million.

  • Genmab A's Current Deferred Revenue rose 4179.1% to $95.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $95.0 million, marking a year-over-year increase of 4179.1%. This contributed to the annual value of $95.0 million for FY2025, which is 4179.1% up from last year.
  • According to the latest figures from Q4 2025, Genmab A's Current Deferred Revenue is $95.0 million, which was up 4179.1% from $67.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Current Deferred Revenue peaked at $95.0 million during Q4 2025, and registered a low of $67.0 million during Q4 2024.
  • Moreover, its 3-year median value for Current Deferred Revenue was $68.5 million (2024), whereas its average is $72.8 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 563.38% in 2024, then skyrocketed by 4179.1% in 2025.
  • Genmab A's Current Deferred Revenue (Quarter) stood at $71.0 million in 2023, then dropped by 5.63% to $67.0 million in 2024, then soared by 41.79% to $95.0 million in 2025.
  • Its last three reported values are $95.0 million in Q4 2025, $67.0 million for Q3 2025, and $67.0 million during Q2 2025.